Since levels of pRb decreased in ER+ breast cancer lines treated with abemaciclib, and early phase clinical data suggested preferential antitumor activity in patients with HR+ disease [17], we further examined the effects of abemaciclib in ER+ cell lines. Here, ESR1 is linked to breast cancer.